Organon Past Earnings Performance
Past criteria checks 0/6
Organon's earnings have been declining at an average annual rate of -24.4%, while the Pharmaceuticals industry saw earnings growing at 12.2% annually. Revenues have been declining at an average rate of 0.2% per year. Organon's return on equity is 24.9%, and it has net margins of 3%.
Key information
-24.39%
Earnings growth rate
-24.76%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | -0.18% |
| Return on equity | 24.87% |
| Net Margin | 3.01% |
| Next Earnings Update | 07 May 2026 |
Recent past performance updates
Recent updates
Organon Takeover At $15? Probably Not, Here's Why
Apr 13The Market Lifts Organon & Co. (NYSE:OGN) Shares 25% But It Can Do More
Jan 29
Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67
Nov 14Investors Give Organon & Co. (NYSE:OGN) Shares A 41% Hiding
Nov 06Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge
May 08Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02
May 04Organon (NYSE:OGN) Use Of Debt Could Be Considered Risky
Apr 28Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Mar 24Why Organon Is A Top Pick For Income Investors
Mar 18Organon's (NYSE:OGN) Dividend Will Be $0.28
Feb 17Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Jan 17Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Dec 13Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
Nov 13The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 04Revenue & Expenses Breakdown
How Organon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 6,216 | 187 | 1,719 | 366 |
| 30 Sep 25 | 6,301 | 501 | 1,747 | 405 |
| 30 Jun 25 | 6,281 | 700 | 1,754 | 432 |
| 31 Mar 25 | 6,294 | 750 | 1,738 | 453 |
| 31 Dec 24 | 6,403 | 864 | 1,749 | 469 |
| 30 Sep 24 | 6,409 | 1,301 | 1,677 | 473 |
| 30 Jun 24 | 6,346 | 1,000 | 1,793 | 499 |
| 31 Mar 24 | 6,347 | 1,047 | 1,807 | 511 |
| 31 Dec 23 | 6,263 | 1,023 | 1,891 | 528 |
| 30 Sep 23 | 6,150 | 585 | 1,892 | 536 |
| 30 Jun 23 | 6,168 | 754 | 1,794 | 526 |
| 31 Mar 23 | 6,145 | 746 | 1,766 | 504 |
| 31 Dec 22 | 6,174 | 917 | 1,702 | 471 |
| 30 Sep 22 | 6,292 | 1,011 | 1,717 | 439 |
| 30 Jun 22 | 6,355 | 1,107 | 1,665 | 398 |
| 31 Mar 22 | 6,365 | 1,304 | 1,658 | 368 |
| 31 Dec 21 | 6,304 | 1,351 | 1,669 | 339 |
| 30 Sep 21 | 6,314 | 1,525 | 1,620 | 289 |
| 30 Jun 21 | 6,327 | 1,762 | 1,553 | 257 |
| 31 Mar 21 | 6,258 | 1,917 | 1,421 | 232 |
| 31 Dec 20 | 6,532 | 2,256 | 1,356 | 210 |
| 31 Dec 19 | 7,777 | 3,306 | 1,443 | 220 |
| 31 Dec 18 | 9,777 | 2,153 | 1,956 | 365 |
| 31 Dec 17 | 10,500 | 1,801 | 2,250 | 355 |
Quality Earnings: OGN has a large one-off loss of $348.0M impacting its last 12 months of financial results to 31st December, 2025.
Growing Profit Margin: OGN's current net profit margins (3%) are lower than last year (13.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OGN's earnings have declined by 24.4% per year over the past 5 years.
Accelerating Growth: OGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: OGN had negative earnings growth (-78.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-3.2%).
Return on Equity
High ROE: Whilst OGN's Return on Equity (24.87%) is high, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 21:22 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Organon & Co. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Jason Matthew Gerberry | BofA Global Research |